We report a novel 9q31.2q32 (chr9: 109195179-113974353, hg 18) microdeletion characterized by fatigue, muscle cramps, short stature, delayed puberty, sensorineural hearing loss, and mild developmental delay. Overlapping microdeletions reported in this region also demonstrate facial dysmorphism, skeletal anomalies, cleft palate, and cardiac valvular abnormalities. In comparing these cases, we suggest critical region of chr9: 109711873-113407621 (hg 18).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389485 | PMC |
| http://dx.doi.org/10.1002/ccr3.1970 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Griscelli syndrome: Erdheim-Chester disease-like local presentation progressing to accelerated phase.
Turk J Pediatr
November 2024
Division of Pediatric Immunology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Türkiye.
Background: Griscelli syndrome (GS) is a rare genetic disorder characterized by oculocutaneous albinism and variable immune dysfunction. Among three distinct types of GS, occurring due to different genetic mutations; GS type 1 presents with neurological manifestations, hemophagocytic lymphohistiocytosis (HLH) generally develops in GS type 2, and GS type 3 primarily exhibits oculocutaneous albinism. HLH, a life-threatening condition with excessive immune activation, may occur secondary to various triggers, including infections, and develop in different tissues, as well as in the testis, similar to Erdheim-Chester disease.
View Article and Find Full Text PDFDiagnosis of Congenital Cytomegalovirus in a 14-Month-Old Patient Presenting with Sensorineural Hearing Loss: Storing Dry Blood Samples.
Turk Arch Pediatr
January 2025
Division of Child Neurology, Department of Pediatrics, Kocaeli University School of Medicine, Kocaeli, Türkiye.
Chronic Myeloid Leukemia Presenting With Bilateral Optic Neuropathy and Sensorineural Hearing Loss as the First Clinical Presentation: A Case Report.
Case Rep Neurol Med
January 2025
Department of Pathology, Mayo Hospital, King Edward Medical University, Lahore, Pakistan.
Chronic myeloid leukemia (CML) is a myeloproliferative disorder that commonly manifests in chronic, accelerated, or blast phase. Typically observed in individuals aged 60-65 years, CML is infrequently diagnosed in adolescents. The usual presentation in late adulthood involves nonspecific symptoms such as fever, fatigue, and weight loss, with rare reports of initial neurological involvement.
View Article and Find Full Text PDFCognitive Disorders In Acquired Sensorineural Hearing Loss, At The Ent Department Of The "Village Bondeko" Center, In Kinshasa.
Neuropsychiatr Dis Treat
January 2025
Department of Specialties, Otolaryngology Department, University Clinics of Kinshasa, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Context: Several data from the literature have focused on the relationship between congenital sensorineural hearing loss, as well as acquired hearing loss, and their impact on cognition and the risk of dementia. However, few studies have been conducted on this subject in countries where access to hearing rehabilitation measures is limited. Thus, the objective of the present study was to investigate the relationship between sensorineural hearing loss and cognitive disorders in a correlational approach.
View Article and Find Full Text PDFLong-term Prospective Comparative Analysis of Ototoxic and Survival Outcomes of Sequential Boost and Simultaneous Integrated Boost of Volumetric Modulated Arc Therapy for Head-Neck Carcinomas.
Turk Arch Otorhinolaryngol
January 2025
All India Institute of Medical Sciences, Department of Otorhinolaryngology, Jodhpur, Rajasthan, India.
Objective: To compare the ototoxicity and survival in head and neck carcinoma patients treated with sequential (SEQ) and simultaneous integrated boost (SIB) of volumetric modulated arc therapy (VMAT).
Methods: This long-term prospective study enrolled patients with histologically confirmed head and neck carcinoma, all receiving VMAT treatment. Audiological assessments were done using various tests at baseline, two weeks, treatment completion, six months, and 12 months.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!